Nasdaq · Biological Products, (No Diagnostic Substances)
10 entities across 7 jurisdictions. Read directly from the company’s own 10-K EX-21 filed 2026-08-24 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| Research and Diagnostic Systems Inc. (R&D Systems) | Minnesota | |
| Bio-Techne China Co. Ltd | China | |
| ProteinSimple | Delaware | |
| ProteinSimple Ltd. | Canada | |
| Novus Biologicals, LLC | Delaware | |
| Bio-Techne Ltd. | United Kingdom | |
| Advanced Cell Diagnostics, Inc. | California | |
| Asuragen, Inc. | Delaware | |
| Cyvek, Inc | Delaware | |
| Lunaphore SA | Switzerland |
Two standard screens, computed from the XBRL in FY2026 against FY2025. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2021 | $931.0M | $140.4M | $307.9M | 68.0% | 40,483,000 |
| FY2022 | $1.1B | $272.1M | $280.4M | 68.4% | 41,029,000 |
| FY2023 | $1.1B | $285.3M | $216.1M | 67.7% | 161,855,000 |
| FY2024 | $1.2B | $168.1M | $236.1M | 66.4% | 160,774,000 |
| FY2025 | $1.2B | $73.4M | $256.6M | 64.8% | 159,717,000 |
| FY2026 | $1.2B | $181.9M | $263.2M | 65.8% | 157,009,000 |
15 institutions tracked — 8 added, 5 reduced, 2 opened a new position, 1 sold out. Index money added 2,112,321 shares while active managers cut 2,834,328.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | Active fund | 10,305 | −5,109,880 | $728,049 |
| FMR LLC | Active fund | 12,794,784 | +4,894,856 | $904.0M |
| PRICE T ROWE ASSOCIATES INC /MD/ | Active fund | 226,000 | −2,221,331 | $16.0M |
| MORGAN STANLEY | Active fund | 6,374,717 | −2,158,156 | $450.4M |
| BlackRock, Inc. | Index | 14,025,816 | +1,761,303 | $990.9M |
| CITADEL ADVISORS LLC | Hedge fund | 1,050,118 | +875,916 | $74.2M |
| JPMORGAN CHASE & CO | Active fund | 1,862,805 | +837,700 | $132.6M |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 5,351,464 | +239,044 | $377.5M |
| Capital World Investors | Active fund | 536,962 | +227,199 | $37.9M |
| BANK OF AMERICA CORP /DE/ | Active fund | 955,237 | −158,336 | $67.5M |
| STATE STREET CORP | Index | 5,980,370 | +111,974 | $422.5M |
| AQR CAPITAL MANAGEMENT LLC | Hedge fund | 24,785 | −43,069 | $1.8M |
| Bridgewater Associates, LP | Hedge fund | 26,750 | +20,773 | $1.9M |
NORGES BANK, SOROS FUND MANAGEMENT LLC hold a position with no prior filing to compare against, so their change is unknown rather than zero — and they are left out of the totals above.
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
What the company actually paid out and bought back, as reported — the record behind any yield figure.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
BIO-TECHNE Corp files under SIC 2836 — all 11 biological products, (no diagnostic substances) companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
